1107614-33-4Relevant articles and documents
Synthesis of 14C-labeled and 13C-, 15N-labeled dasatinib and its piperazine N-dealkyl metabolite
Allentoff, Alban J.,Lago, Michael W.,Ogan, Marc,Chen, Bang-Chi,Zhao, Rulin,Iyer, Ramaswarmy A.,Christopher, Lisa J.,Rinehart, J. Kent,Balasubramanian, Balu,Bonacorsi Jr., Samuel J.
, p. 41 - 47 (2008/09/20)
Dasatinib (SPRYCEL) is a multiple kinase inhibitor approved for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in patients with resistance to prior therapy, including imatinib mesylate (Glee